That was the position that we took early on. We knew there was discontent within the U.S., particularly in the House where that they did not agree with elements of what the U.S. had negotiated and there were discussions actively taking place.
Mexico ratified it very quickly. The U.S. ratified it fairly quickly as well, but we knew there was still a negotiation going on. We had several issues that were of significant importance to us in that negotiation, particularly the issue of the date of the term for biologic drugs, which would have had a significant impact on us; the issue of getting dispute settlement processes that would actually work as a part of that as well; and provisions on labour and the environment. The negotiation was not done, so we saw little point in conducting a full economic analysis until the negotiations were actually completed.